NOVEL HUMAN PHOSPHOLEMMAN-LIKE PROTEIN

Abstract: The present invention provides a novel human phospholemman-like protein (HPLP) and the polynucleotides which identify and encode HPLP. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HPLP and for a method for producing the protein. The invention also provides pharmaceutical compositions containing HPLP and the use of such compositions for the prevention or treatment of diseases associated with the expression of HPLP. Additionally, the invention provides antisense molecules to HPLP and their use in the treatment of diseases associated with the expression of HPLP. The invention also provides diagnostic assays which utilize polynucleotides which hybridize with naturally occurring sequences encoding HPLP and antibodies which specifically bind to the protein.

Description: NOVEL HUMAN PHOSPHOLEMMAN-LIKE PROTEIN TECHNICAL FIELD The present invention relates to nucleic acid and amino acid sequences of a novel human phospholemman-like protein and to the use of these sequences in the diagnosis, study, prevention, and treatment of disease. BACKGROUND ART Phospholemman (PLM) is the major plasmalemmal substrate for cAMP-dependent protein kinase (cAMPK) and protein kinase C (PKC). Canine and murine PLM are expressed at high levels in heart, skeletal muscle, and liver, and at low levels in breast, brain, lung, stomach, kidney, and colon (Palmer C et al (1991) J Biol Chem 266: 11126-1 1130; Moorman JR et al (1992) J Biol Chem 267:14551-14554). PLM is a membrane protein which consists of 72 amino acids and has a calculated molecular weight of 8409. The native protein has an apparent molecular weight of 15 kdal from polyacrylamide gel electrophoresis. A distinguishing feature of PLM is its highly basic nature, with a calculated isoelectric point of 9.7 (Palmer C et al, supra). PLM consists of an acidic extracellular amino-terminal domain, a single uncharged transmembrane domain, and an extremely basic cytoplasmic carboxy-terminal domain. The cytoplasmic domain contains consensus cAMPK and PKC phosphorylation sites. The phosphorylation of PLM by PKC and cAMPK is regulated by insulin and adrenaline, respectively (Walaas S et al (1994) Biochem J 304:635-640). PLM phosphorylation in cardiac muscle occurs after activation of either a- or b- adrenergic receptors, and correlates with an increase in contractility (Lindemann JP (1986) J Biol Chem 261 :4860-4867). Expression of PLM in Xenopus oocytes injected with PLM mRNA coincides with the appearance of voltage-activated chloride currents (Moorman et al, supra). Immunoaffinity- purified recombinant PLM added to planar phospholipid bilayers produces unitary anion currents (Moorman JR et al (1995) Nature 377:737-740). The high selectivity of the PLM channel for the sulfonic amino acid taurine suggests that PLM channels link signal transduction cascades to cell volume regulation. The investigators report that PLM is the smallest membrane protein known to form an ion channel (Moorman et al (1995), supra). Mat-8. an 8-kDa transmembrane protein related to PLM, is expressed in murine breast tumor lines transformed by Neu or Ras oncoproteins. Morrison BW et al ((1994) Oncogene 9:3417-3426) proposed that Mat-8 is a marker of the cell type preferentially transformed by neu or v-Ha-rαs oncogenes. A human Mat-8 homolog is expressed both in primary breast tumors and in breast tumor cell lines. Murine Mat-8 is also expressed in uterus, stomach, colon, and at low levels in virgin breast, ovary, lung, small intestine and thymus. In contrast to PLM, Mat-8 is not expressed in liver, heart or skeletal muscle, which suggests distinct cellular functions for the two molecules (Morrison BW et al (1995) J Biol Chem 270:2176-2182). The extracellular and transmembrane domains of Mat-8 are homologous to those of PLM. However, the cytoplasmic domain of Mat-8 is unrelated to PLM and contains no consensus phosphorylation sites for PKC or cAMPK. Expression of Mat-8 in Xenopus oocytes induces voltage-activated chloride currents similar to those induced by expression of PLM (Morrison et al (1995), supra). However, direct ion channel formation by Mat-8 has not been reported. The ability of Mat-8 protein to induce chloride channel activity, together with its tissue distribution (discussed above), suggests that this protein may be involved in the regulation of transepithelial transport in tissues containing absorptive or secretory epithelia. Additional proteins similar in structure to PLM and Mat-8 have been found to induce ion channel activity when expressed in Xenopus oocytes . Channel inducing factor (CHIF), found in colon and kidney, consists of a single transmembrane domain and exhibits 50% sequence similarity to PLM (Attali B et al (1995) Proc Natl Acad Sci USA 92: 6092-6096). Xenopus oocytes injected with CHIF mRNA exhibit K+ specific channel activity. Slow-activating voltage dependent potassium ion channel (IsK; Takumi T et al (1988) Science 242:1042-1045) is a single transmembrane domain glycoprotein present in epithelial cells, heart, uterus and lymphocytes (Attali B et al (1993) Nature 365:850-852). IsK induces both K+ and Cl- currents when expressed in Xenopus oocytes and HEK 293 cells. The accumulated evidence suggests that CHIF and IsK act as regulatory subunits of pre-existing channel complexes rather than as channels per se (Attali B et al (1995), supra; Ben-Efraim I et al (1996) J Biol Chem 271 :8768-8771). The sodium potassium ATPase (Na,K- ATPase) g-subunit, formerly known as the Na,K- ATPase proteolipid. is a small membrane protein that co-purifies with the a- and b-subunits of Na,K-ATPase (Mercer RW et al (1993) J Cell Biol 121 :579-586). The g-subunit is a small membrane protein consisting of 58 amino acids with a single transmembrane domain. This transmembrane domain is structurally related to the transmembrane domains of other PLM-like proteins. The g-subunit may act as a regulator of the ATP-dependent ion channel activity of Na,K-ATPase. Discovery and molecular characterization of new members of the family of PLM-like proteins satisfies a need in the art by providing new opportunities to understand and modulate physiological processes including neurotransmitter release, transepithelial transport, membrane potential stabilization, signal transduction and cell volume regulation. DISCLOSURE OF THE INVENTION The present invention features a novel human PLM-like protein, hereinafter referred to as HPLP, having chemical and structural homology to PLM. Mat-8, CHIF, and Na.K-ATPase g- subunit. Accordingly, the invention features a substantially purified HPLP, encoded by amino acid sequence of SEQ ID NOT, having structural characteristics of the family of PLM-like proteins. One aspect of the invention features isolated and substantially purified polynucleotides which encode HPLP. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2. In addition, the invention features nucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2. The invention further relates to nucleic acid sequence encoding HPLP. oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof. The present invention also relates to an expression vector which includes polynucleotide encoding HPLP, its use to transform host cells or organisms and methods for producing the protein. The invention also relates to antibodies which bind specifically to HPLP and to a pharmaceutical composition comprising substantially purified HPLP. BRIEF DESCRIPTION OF DRAWINGS Figures 1A and IB shows the amino acid (SEQ ID NO: l) and nucleic acid sequences (SEQ ID NO:2) of the novel HPLP of the present invention produced using MacDNAsis software (Hitachi Software Engineering Co Ltd, San Bruno CA). Figure 2 shows the amino acid sequence alignments among HPLP (SEQ ID NOT), canine PLM (SEQ ID NO:3, GI 108084. Palmer et al, supra), human MAT-8 (SEQ ID NO:4, GI 1085026, Morrison et al, supra), rat CHIF (SEQ ID NO:5, GI 951423, Attali B et al (1995), supra), and mouse Na,K- ATPase g-subunit (SEQ ID NO:6, GI 51 1 12, Mercer RW et al. supra). Sequences were aligned using the multisequence alignment program of DNAStar™ software (DNAStar Inc, Madison WI). Figure 3 shows the hydrophobicity plot (generated using MacDNAsis software) for HPLP, SEQ ID NO: 1 ; the X axis reflects amino acid position, and the negative Y axis, hydrophobicity. -J- MODES FOR CARRYING OUT THE INVENTION Definitions "Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or polynucleotide. and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, amino acid sequence as used herein refers to peptide or protein sequence. "Consensus" as used herein may refer to a nucleic acid sequence 1) which has been resequenced to resolve uncalled bases, 2) which has been extended using XL-PCR (Perkin Elmer, Norwalk CT) in the 5' and/or the 3' direction and resequenced, 3) which has been assembled from the overlapping sequences of more than one Incyte clone GCG Fragment Assembly System, (GCG, Madison WI), or 4) which has been both extended and assembled. "Peptide nucleic acid" as used herein refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine. and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen PE et al (1993) Anticancer Drug Des 8:53-63). A "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent. An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring HPLP. A "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As used herein, HPLP refers to the amino acid sequence of substantially purified HPLP obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic or recombinant. A "variant" of HPLP is defined as an amino acid sequence differs by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, eg, replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, eg, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNAStar software. The term "biologically active" refers to HPLP having structural, regulatory or biochemical functions of a naturally occurring HPLP. Likewise, "immunologically active" defines the capability of the natural, recombinant or synthetic HPLP, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. The term "agonist" refers to a molecule which, when bound to HPLP, causes a change in HPLP which modulates the biological activity of HPLP. The term "antagonist" refers to a molecule which, when bound to HPLP. blocks the binding of an agonist to HPLP. which prevents the agonist-induced change in the biological activity of HPLP. Agonists and antagonists may include proteins, nucleic acids, carbohydrates, or other molecules which bind to HPLP. The term "modulate" as used herein refers to a change or an alteration in the biological activity of HPLP. Modulation may be an increase or a decrease in biological activity, a change in binding characteristics, or any other change in the biological properties of HPLP. The term "derivative" as used herein refers to the chemical modification of a nucleic acid encoding HPLP or the encoded HPLP. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of natural HPLP. As used herein, the term "substantially purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90%o free from other components with which they are naturally associated. The term "hybridization" as used herein shall include "any process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY). Amplification is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction technologies well known in the art (Dieffenbach CW and GS Dveksler (1995) PCR Primer, a Laboratory Manual. Cold Spring Harbor Press. Plainview NY). "Stringency" typically occurs in a range from about Tm-5°C (5°C below the Tm of the probe)to about 20°C to 25°C below Tm. As will be understood by those of skill in the art, stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. Preferred Embodiments The present invention relates to a novel human phospholemman-like protein (HPLP) originally identified among the cDNAs from a library constructed from a human neuronal teratocarcinoma cell line and to the use of the nucleic acid and amino acid sequences in the study, diagnosis, prevention and treatment of disease. The consensus nucleotide sequence, disclosed herein, was derived from the following overlapping and/or extended nucleic acid sequences: 97397 (PITUNOROl), 256782 and 260077 (HNT2RAT01), 261205 and 261745 (HNT2AGT01), 397907 (PITUNOT02), 555327 (SCORNOT01), 658934 (BRAINOT03), 691325 and 691710 (LUNGTUT02), 743664, 744824, 749657, and 753284 (BRAITUT01), and 920208 and 920330 (RATRNOT02). Northern analysis using the LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto CA) shows that mRN A encoding HPLP is abundant in neuronal tissues (brain, neuronal cell lines and spinal cord). HPLP mRNA is also found in pituitary gland, heart, and lung. It must be noted that naturally occurring expression of HPLP is not necessarily limited to these cells and tissues. The present invention also encompasses HPLP variants. A preferred HPLP variant is one having at least 80% amino acid sequence similarity to the amino acid sequence (SEQ ID NO:l), a more preferred HPLP variant is one having at least 90%> amino acid sequence similarity to SEQ ID NO:l and a most preferred HPLP variant is one having at least 95% amino acid sequence similarity to SEQ ID NOT. Nucleic acid encoding the human HPLP of the present invention was first identified in cDNA, Incyte Clone 261205 (SEQ ID NO:2), through a computer- generated search for amino acid sequence alignments. The nucleic acid sequence, SEQ ID NO:2, encodes the amino acid sequence, SEQ ID NOT . The present invention is based, in part, on the chemical and structural homology among HPLP, PLM (SEQ ID NO:3; GI 108084; Palmer C et al, supra), MAT-8 (SEQ ID NO:4; GI 1085026; Morrison B et al (1995), supra), CHIF (SEQ ID NO:5; GI 951423, Attali B et al (1995), supra), and Na,K-ATPase g-subunit (SEQ ID NO:6, GI 51112. Mercer RW et al, supra). PLM, Mat-8, CHIF, and Na.K- ATPase g-subunit have, respectively, 46%, 31%, 25%, and 27% sequence identity to HPLP. The identity increases within the transmembrane domains of these proteins; the transmembrane domains of PLM, Mat-8, CHIF, and Na,K-ATPase g-subunit have, respectively. 60%), 45%, 40%. and 60% sequence identity with the predicted transmembrane domain of HPLP. The HPLP protein sequence consists of 95 amino acids. From the amino acid sequence alignments (Figure 2) and the hydrophobicity plot (Figure 3), HPLP is translated as a pre-protein. The HPLP signal peptide is predicted to extend from residue 1 to residue 21. A single transmembrane domain is predicted to extend from residues 39 to 58, which terminates in a positively-charged membrane stop transfer sequence (RRCK) at residues 59 to 62. The HPLP Coding Sequences The extended and assembled nucleic acid and deduced amino acid sequences of HPLP are shown in Figures 1 A and IB. In accordance with the invention, any nucleic acid sequence which encodes HPLP can be used to generate recombinant molecules which express HPLP. In a specific embodiment described herein, a partial sequence encoding HPLP was first isolated as Incyte Clone 261205 from an hNT2 cell line cDNA library (HNT2AGT01). It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of HPLP-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene may be produced. The invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence encoding naturally occurring HPLP. and all such variations are to be considered as being specifically disclosed. Although nucleotide sequences which encode HPLP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring sequence under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HPLP or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HPLP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence. A DNA sequence, or portions thereof, encoding HPLP or its derivative may be produced entirely by synthetic chemistry. After synthesis, the gene may be inserted into any of the many available DNA vectors and cell systems using reagents that generally available. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HPLP or any portion thereof. Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of SEQ ID NO:2 under various conditions. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques. Methods in Enzymology. Vol 152, Academic Press, San Diego CA) incorporated herein by reference, and on the salt concentrations under which the steps of the process are carried out . Altered nucleic acid sequences encoding HPLP which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent HPLP. The protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HPLP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of HPLP is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine: and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine. alanine; asparagine. glutamine; serine, threonine phenylalanine, and tyrosine. Included within the scope of the present invention are alleles encoding HPLP. As used herein, an "allele" or "allelic sequence" is an alternative form of the nucleic acid sequence encoding HPLP. Alleles result from a mutation, ie, a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence. Methods for DNA sequencing may be used which are well known in the art and employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland OH)), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI 377 DNA sequencers (Perkin Elmer). Extending the Polynucleotide Sequence The polynucleotide sequence encoding HPLP may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, Gobinda et al (1993; PCR Methods Applic 2:318-22) use "restriction-site" polymerase chain reaction (PCR) as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase. Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia T et al (1988) Nucleic Acids Res 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth MN). or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template. Capture PCR (Lagerstrom M et al (1991) PCR Methods Applic 1 :11 1-19) is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR. Another method which may be used to retrieve unknown sequence is walking PCR (Parker JD et al (1991) Nucleic Acids Res 19:3055-60), which involves targeted gene walking. Alternatively, PCR. nested primers, PromoterFinder™ (Clontech. Palo Alto CA) and PromoterFinder libraries can be used to walk in genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred libraries for screening for full length cDNAs are those which have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region. Capillary electrophoresis may be used to analyze either the size or confirm the nucleotide sequence in sequencing or PCR products. Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton CA), and other companies. Capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled devise camera. Output/light intensity is converted to electrical signal using appropriate software (eg. Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample. The reproducible sequencing of up to 350 bp of Ml 3 phage DNA in 30 min has been reported (Ruiz-Martinez MC et al (1993) Anal Chem 65:2851-8). Expression of the Nucleotide Sequence In accordance with the present invention, polynucleotide sequences which encode HPLP. fragments of the polypeptide, fusion proteins or functional equivalents thereof may be used in recombinant DNA molecules that direct the expression of HPLP in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to clone and express HPLP. As will be understood by those of skill in the art, it may be advantageous to produce HPLP-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host (Murray E et al (1989) Nuc Acids Res 17:477-508) can be selected, for example, to increase the rate of HPLP expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence. The nucleotide sequences of the present invention can be engineered in order to alter HPLP-encoding sequence for a variety of reasons, including but not limited to. alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, eg, site-directed 5 mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, etc. In another embodiment of the invention, a natural, modified or recombinant HPLP- encoding sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of HPLP activity, it may be useful to 10 encode a chimeric HPLP protein that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between HPLP and the heterologous protein sequence, so that the HPLP may be cleaved and substantially purified away from the heterologous moiety. In an alternate embodiment of the invention, the sequence encoding HPLP may be 15 synthesized, whole or in part, using chemical methods well known in the art (see Caruthers MH et al (1980) Nuc Acids Res Symp Ser 215-23. Horn T et al(1980) Nuc Acids Res Symp Ser 225-32, etc). Alternatively, the protein itself may be produced using chemical methods to synthesize an amino acid sequence for HPLP. whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge JY et al (1995) Science 20 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (eg, Creighton (1983) Proteins. Structures and Molecular 25 Principles. WH Freeman and Co, New York NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (eg, the Edman degradation procedure; Creighton, supra). Additionally the amino acid sequence of HPLP. or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide. 30 Expression Systems In order to express a biologically active HPLP, the nucleotide sequence encoding HPLP or its functional equivalent, is inserted into an appropriate expression vector, ie, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing a sequence encoding HPLP and appropriate transcriptional or translational controls. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination or genetic recombination. Such techniques are described in Sambrook et al (1989) Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Press, Plainview NY and Ausubel FM et al (1989) Current Protocols in Molecular Biology. John Wiley & Sons, New York NY. A variety of expression vector/host systems may be utilized to contain and express a sequence encoding HPLP. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (eg, baculovirus); plant cell systems transfected with virus expression vectors (eg, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (eg, Ti or pBR322 plasmid); or animal cell systems. The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3 'and 5' untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla CA) or pSportl (Gibco BRL) and ptrp-lac hybrids and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (eg, heat shock, RUBISCO; and storage protein genes) or from plant viruses (eg, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HPLP, vectors based on SV40 or EBV may be used with an appropriate selectable marker. In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HPLP. For example, when large quantities of HPLP are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HPLP may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509); and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will. In the yeast, Saccharomyces cerevisiae. a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel et al (supra) and Grant et al (1987) Methods in Enzymology 153:516-544. In cases where plant expression vectors are used, the expression of a sequence encoding HPLP may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV (Brisson et al (1984) Nature 310:51 1-514) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu et al (1987) EMBO J 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al (1984) EMBO J 3:1671-1680; Broglie et al (1984) Science 224:838-843); or heat shock promoters (Winter J and Sinibaldi RM (1991) Results Probl Cell Differ 17:85-105) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S or Murry LE in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill New York NY, pp 191-196 or Weissbach and Weissbach (1988) Methods for Plant Molecular Biology. Academic Press, New York NY, pp 421-463. An alternative expression system which may be used to express HPLP is an insect system. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequence encoding HPLP may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the sequence encoding HPLP will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect £. frugiperda cells or Trichoplusia larvae in which HPLP is expressed (Smith et al (1983) J Virol 46:584; Engelhard EK et al (1994) Proc Nat Acad Sci 91 :3224-7). In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a sequence encoding HPLP may be ligated into an adenovirus transcription/ translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential El or E3 region of the viral genome will result in a viable virus capable of expressing in infected host cells (Logan and Shenk (1984) Proc Natl Acad Sci 81 :3655-59). In addition, transcription enhancers, such as the rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. Specific initiation signals may also be required for efficient translation of a sequence encoding HPLP. These signals include the ATG initiation codon and adjacent sequences. In cases where the sequence encoding HPLP, its initiation codon and upstream sequences are inserted into the most appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf D et al (1994) Results Probl Cell Differ 20:125-62; Bittner et al (1987) Methods in Enzymol 153:516-544). In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to. acetylation. carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein. For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HPLP may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to. the herpes simplex virus thymidine kinase (Wigler M et al (1977) Cell 1 1 :223-32) and adenine phosphoribosyltransferase (Lowy I et al (1980) Cell 22:817-23) genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler M et al (1980) Proc Natl Acad Sci 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin F et al (1981) J Mol Biol 150: 1-14) and als or pat. which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan. or hisD, which allows cells to utilize histinol in place of histidine (Hartman SC and RC Mulligan (1988) Proc Natl Acad Sci 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins. β glucuronidase and its substrate. GUS. and luciferase and its substrate, luciferin. being widely used not only to identify transformants. but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes CA et al (1995) Methods Mol Biol 55:121-131). Identification of Transformants Containing the Polynucleotide Sequence Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the sequence encoding HPLP is inserted within a marker gene sequence, recombinant cells containing the sequence encoding HPLP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with the sequence encoding HPLP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem sequence as well. Alternatively, host cells which contain the sequence encoding HPLP and expressing HPLP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to. DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein. The presence of the polynucleotide sequence encoding HPLP can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of the sequence encoding HPLP. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the nucleic acid sequence to detect transformants containing DNA or RNA encoding HPLP. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides. preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplimer. A variety of protocols for detecting and measuring the expression of HPLP, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HPLP is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, a Laboratory Manual. APS Press, St Paul MN) and Maddox DE et al (1983. J Exp Med 158:121 1). A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the HPLP-encoding sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides. A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides. enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors. inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817.837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275.149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567 incorporated herein by reference. Purification of HPLP Host cells transformed with a nucleotide sequence encoding HPLP may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing sequence encoding HPLP can be designed with signal sequences which direct secretion of HPLP through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join the sequence encoding HPLP to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12:441-53; cf discussion of vectors infra containing fusion proteins). HPLP may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin. and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and HPLP is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding HPLP and nucleic acid sequence encoding 6 histidine residues followed by thioredoxin and an enterokinase cleavage site. The histidine residues facilitate purification while the enterokinase cleavage site provides a means for purifying HPLP from the fusion protein. In addition to recombinant production, fragments of HPLP may be produced by direct peptide synthesis using solid-phase techniques (cf Stewart et al (1969) Solid-Phase Peptide Synthesis. WH Freeman Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154). In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer. Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of HPLP may be chemically synthesized separately and combined using chemical methods to produce the full length molecule. Uses of HPLP The rationale for diagnostic and therapeutic uses of sequences encoding HPLP is based on the nucleotide and amino acid sequences, their homology to PLM-like transmembrane proteins associated with ion transport, their tissue distribution primarily in brain and nervous system tissues, but also in pituitary, heart, and lung, and the known associations and functions of PLM- like transmembrane proteins. HPLP may modify or regulate ion currents generated in the central and/or autonomic nervous system. Therefore, mutations in or altered expression of HPLP may be associated with diseases and conditions relating to defective ion transport. Such disorders may include, but are not limited to, defects in nerve signal transmission, membrane potential generation, or fluid volume regulation, such as Alzheimer's disease. Parkinson disease ' s. Huntington disease's, amyotrophic lateral sclerosis, and hydrocephalus. HPLP or its fragments may be used to identify specific molecules that modulate the activity of HPLP. such as agonists, antagonists or inhibitors. Furthermore, HPLP is useful as an investigative tool in the study of the control of ion transport and membrane potential in both normal and diseased cells. HPLP-specific antibodies are useful for the diagnosis of conditions and diseases associated with expression of the polypeptides. Antibodies specifically recognizing HPLP may be used to quantitate HPLP for diagnostic purposes. A diagnostic test for altered expression of HPLP may accelerate diagnosis and proper treatment of conditions associated with HPLP. The HPLP nucleic acid sequence of SEQ ID NO:2 can be incorporated into effective eukaryotic expression vectors and directly administered into somatic cells for gene therapy. In like manner, RNA transcripts produced in vitro may be encapsulated in and administered via liposomes. Such vectors and transcripts may function transiently or may be incorporated into the host chromosomal DNA for longer term expression. In vivo delivery of genetic constructs into subjects is developed to the point of targeting specific cell types. The delivery to specific cells has been accomplished, for instance, by complexing nucleic acids with proteinous ligands that recognize cell specific receptors which mediate uptake (cf Wu GY et al (1991) J Biol Chem 266:14338-42). Alternatively, recombinant nucleic acid constructs may be injected directly for local uptake and integration (Jiao S et al (1992) Human Gene Therapy 3:21-33). HPLP Antibodies HPLP-specific antibodies are useful for the diagnosis and treatment of conditions and diseases associated with expression of HPLP. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric. single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, ie, those which inhibit dimer formation, are especially preferred for diagnostics and therapeutics. It is not necessary that the portion of HPLP used for antibody induction have biological activity; however, the protein fragment, or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, and preferably at least 10 amino acids. Preferably, they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HPLP amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to HPLP. For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with HPLP or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are potentially useful human adjuvants. Monoclonal antibodies to HPLP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) Immunol Today 4:72; Cote et al (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) Monoclonal Antibodies and Cancer Therapy, Alan R Liss Inc. New York NY, pp 77-96). In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) Proc Natl Acad Sci 81 :6851-6855; Neuberger et al (1984) Nature 312:604-608; Takeda et al (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,778) can be adapted to produce HPLP-specific single chain antibodies. Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al (1989, Proc Natl Acad Sci 86: 3833-3837), and Winter G and Milstein C (1991 ; Nature 349:293-299). Antibody fragments which contain specific binding sites for HPLP may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD et al (1989) Science 256: 1275-1281). A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between HPLP and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific HPLP protein is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox DE et al (1983, J Exp Med 158: 121 1). Diagnostic Assays Using HPLP Specific Antibodies Particular HPLP antibodies are useful for the diagnosis of conditions or diseases characterized by expression of HPLP or in assays to monitor patients being treated with HPLP, its fragments, agonists or inhibitors. Diagnostic assays for HPLP include methods utilizing the antibody and a label to detect HPLP in human body fluids or extracts of cells or tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known, several of which were described above. A variety of protocols for measuring HPLP, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HPLP is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983) J Exp Med 158:121 1. In order to provide a basis for diagnosis, normal or standard values for HPLP expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with antibody to HPLP under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing various artificial membranes containing known quantities of HPLP with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of disease state. Drug Screening HPLP, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between HPLP and the agent being tested, may be measured. Another technique for drug screening which may be used for high throughput screening of compounds having suitable binding affinity to the HPLP is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO Application 84/03564, published on September 13, 1984, and incorporated herein by reference. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with fragments of HPLP and washed. Bound HPLP is then detected by methods well known in the art. Substantially purified HPLP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding HPLP specifically compete with a test compound for binding HPLP. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HPLP. Uses of the Polynucleotide Encoding HPLP A polynucleotide sequence encoding HPLP or any part thereof may be used for diagnostic and or therapeutic purposes. For diagnostic purposes, the sequence encoding HPLP of this invention may be used to detect and quantitate gene expression in biopsied tissues in which HPLP may be expressed in response to oncogenes. The diagnostic assay is useful to distinguish between absence, presence, and excess expression of HPLP and to monitor regulation of HPLP levels during therapeutic intervention. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, and peptide nucleic acids (PNA). Another aspect of the subject invention is to provide for hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HPLP or closely related molecules. The specificity of the probe, whether it is made from a highly specific region, eg, 10 unique nucleotides in the 5' regulatory region, or a less specific region, eg, especially in the 3' region, and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring HPLP, alleles or related sequences. Probes may also be used for the detection of related sequences and should preferably contain at least 50% of the nucleotides from any of these sequences encoding HPLP. The hybridization probes of the subject invention may be derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements and introns of the naturally occurring sequence encoding HPLP. Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as 32P or 35S. or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like. Other means for producing specific hybridization probes for DNAs include the cloning of nucleic acid sequences encoding HPLP or HPLP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. Diagnostic Use Polynucleotide sequences encoding HPLP may be used for the diagnosis of conditions or diseases with which the expression of HPLP is associated. For example, polynucleotide sequences encoding HPLP may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect HPLP expression. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits. The HPLP-encoding nucleotide sequences disclosed herein provide the basis for assays that detect activation or induction associated with inflammation or disease. The nucleotide sequence may be labeled by methods known in the art and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off. the dye is quantitated and compared with a standard. If the amount of dye in the biopsied or extracted sample is significantly elevated over that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the presence of elevated levels of nucleotide sequences encoding HPLP in the sample indicates the presence of the associated inflammation and/or disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for HPLP expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with HPLP. or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of HPLP run in the same experiment where a known amount of substantially purified HPLP is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients affected by HPLP-associated diseases. Deviation between standard and subject values establishes the presence of disease. Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the profile progress toward or return to the normal or standard pattern. Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months. PCR. may be used as described in US Patent Nos. 4.683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the sequence encoding HPLP. Such oligomers are generally chemically synthesized, but they may be generated enzymatically or produced from a recombinant source. Oligomers generally comprise two nucleotide sequences, one with sense orientation (5'->3') and one with antisense (3'<-5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences. Additionally, methods which may be used to quantitate the expression of a particular molecule include radiolabeling (Melby PC et al 1993 J Immunol Methods 159:235-44) or biotinylating (Duplaa C et al 1993 Anal Biochem 229-36) nucleotides. coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation. A definitive diagnosis of this type may allow health professionals to begin aggressive treatment and prevent further worsening of the condition. Similarly, further assays can be used to monitor the progress of a patient during treatment. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known such as the triplet genetic code, specific base pair interactions, and the like. Therapeutic Use Based upon its homology to the PLM-like proteins and its expression profile, the polynucleotide encoding HPLP disclosed herein may be useful in the treatment of diseases associated with aberrant ion transport. Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense of the sequence encoding HPLP. See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra). The polynucleotides comprising full length cDNA sequence and/or its regulatory elements enable researchers to use the sequence encoding HPLP as an investigative tool in sense (Youssoufian H and HF Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem 60:631-652) regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions. Genes encoding HPLP can be turned off by transfecting a cell or tissue with expression vectors which express high levels of a desired HPLP fragment. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector (Mettler I, personal communication) and even longer if appropriate replication elements are part of the vector system. As mentioned above, modifications of gene expression can be obtained by designing antisense molecules. DNA, RNA or PNA, to the control regions of the sequence encoding HPLP. ie, the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence, are preferred. The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases. transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA were reviewed by Gee JE et al (In: Huber BE and BI Carr (1994) Molecular and Immunologic Approaches. Futura Publishing Co, Mt Kisco NY). Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of the sequence encoding HPLP. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA. GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HPLP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues. RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to. the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine and wybutosine as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine. guanine, thymine. and uridine which are not as easily recognized by endogenous endonucleases. Methods for introducing vectors into cells or tissues include those methods discussed infra and which are equally suitable for in vivo, in vitro and ex vivo therapy. For ex vivo therapy, vectors are introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient is presented in US Patent Nos. 5,399.493 and 5,437,994, disclosed herein by reference. Delivery by transfection and by liposome are quite well known in the art. Furthermore, the nucleotide sequences encoding HPLP disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions. Detection and Mapping of Related Polynucleotide Sequences The nucleic acid sequence encoding HPLP can also be used to generate hybridization probes for mapping the naturally occurring genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include in situ hybridization to chromosomal spreads, flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial PI constructions or single chromosome cDNA libraries as reviewed in Price CM (1993; Blood Rev 7:127-34) and Trask BJ (1991 ; Trends Genet 7:149-54). The technique of fluorescent in situ hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques. Pergamon Press, New York NY. Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265 : 1981 f). Correlation between the location of a the sequence encoding HPLP on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals. In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. A recent example of an STS based map of the human genome was recently published by the Whitehead-MIT Center for Genomic Research (Hudson TJ et al (1995) Science 270:1945-1954). Often the placement of a gene on the chromosome of another mammalian species such as mouse (Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 28. 1995) may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 1 lq22-23 (Gatti et al (1988) Nature 336:577-580). any sequences mapping to that area may represent associated or regulator)' genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier or affected individuals. Pharmaceutical Compositions The present invention relates to pharmaceutical compositions which may comprise nucleotides. proteins, antibodies, agonists, antagonists, or inhibitors, alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. Any of these molecules can be administered to a patient alone, or in combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with excipient(s) or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert. Administration of Pharmaceutical Compositions Administration of pharmaceutical compositions is accomplished orally or parenterally. Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal. or intranasal administration. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Maack Publishing Co, Easton PA). Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees. capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient. Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient. optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol. or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxyme hylcellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked poly vinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, ie, dosage. Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers. Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Manufacture and Storage The pharmaceutical compositions of the present invention may be manufactured in a manner that known in the art, eg, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic. etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose. 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use. After pharmaceutical compositions comprising a compound of the invention formulated in a acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HPLP. such labeling would include amount, frequency and method of administration. Therapeutically Effective Dose Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, eg, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, eg, ED50 (the dose therapeutically effective in 50%) of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state, eg, tumor size and location; age, weight and gender of the patient; diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation. Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of 5 about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature. See US Patent Nos. 4,657,760; 5,206.344; or 5,225.212. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. 10 The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention. INDUSTRIAL APPLICABILITY I cDNA Library Construction The hNT2 cell line exhibits characteristics of a committed neuronal precursor cell which 15 is at an early stage of development. The hNT2 cell line can be induced by retinoic acid (RA) to differentiate, as described in Andrews PW (1984) Dev Biol 103:285-293. For purposes of this invention, hNT2 cells were induced with RA. The method used in the present invention involved suspending hNT2 cells in Dulbecco ' s modified Eagle's medium (DMEM) including 10% fetal bovine serum and penicillin/ streptomycin, treating the cells with 20 10 μM RA twice a week for 5 weeks. The cells were differentially harvested and replated. and exposed to mitotic inhibitors (1 μM cytosine arabinose. 10 μM fluorodeoxyuridine. and 10 μM uridine) for two weeks. The neurons were again differentially harvested, replated and allowed to mature further for 4 weeks in 50%) hNT Neuron Conditioned Medium including DMEM and 10%) fetal bovine serum. This procedure created cells similar to those of the postmitotic neuronal 25 cell line of Lee and Pleasure (hNT2-N cell line) and were named HNT2AGT1 cells. The mRNA used to prepare the HNT2AGT01 library was isolated by Stratagene (La Jolla CA) essentially as described below. First strand cDNA synthesis was accomplished using an oligo d(T) primer/linker which also contained an Xhol restriction site. Second strand synthesis was performed using a combination of DNA polymerase I, coli ligase and RNase H. followed 30 by the addition of an EcoRI adaptor to the blunt ended cDNA. The EcoRI adapted, double- stranded cDNA was then digested with Xhol restriction enzyme and fractionated to obtain sequences which exceeded 800 bp in size. The cDNAs were inserted into the LambdaZap ® vector system (Stratagene); then the vector which contains the pBluescript™ phagemid (Stratagene) was transformed into E. coli host cells strain XLl-BlueMRF™ (Stratagene). The phagemid forms of individual cDNA clones were obtained by the in vivo excision process. Enzymes from both pBluescript and a cotransformed fl helper phage nicked the DNA. initiated new DNA synthesis, and created the smaller, single-stranded circular phagemid molecules which contained the cDNA insert. The phagemid DNA was released, purified, and used to reinfect fresh host cells (SOLR, Stratagene). Presence of the phagemid which carries the gene for β-lactamase allowed transformed bacteria to grow on medium containing ampicillin. II Isolation and Sequencing of cDNA Clones Plasmid DNA was released from the cells and purified using the Miniprep Kit (Catalogue # 77468; Advanced Genetic Technologies Corporation. Gaithersburg MD). This kit consists of a 96 well block with reagents for 960 purifications. The recommended protocol was employed except for the following changes: 1) the 96 wells were each filled with only 1 ml of sterile Terrific Broth (Catalog # 2271 1 , LIFE TECHNOLOGIES™, Gaithersburg MD) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) the bacteria were cultured for 24 hours after the wells were inoculated and then lysed with 60 μl of lysis buffer: 3) a centrifugation step employing the Beckman GS-6R @2900 rpm for 5 min was performed before the contents of the block were added to the primary filter plate; and 4) the optional step of adding isopropanol to TRIS buffer was not routinely performed. After the last step in the protocol, samples were transferred to a Beckman 96-well block for storage. Alternative methods of purifying plasmid DNA include the use of MAGIC MINIPREPS™ DNA Purification System (Catalogue #A7100, Promega, Madison WI)or QIAwell™-8 Plasmid, QIAwell PLUS DNA and QIAwell ULTRA DNA Purification Systems (QIAGEN® Chatsworth CA). The cDNAs were sequenced by the method of Sanger F and AR Coulson (1975; J Mol Biol 94:44 If), using a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with four Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown MA) and Applied Biosystems 377 or 373 DNA Sequencing Systems (Perkin Elmer) and reading frame was determined. III Homology Searching of cDNA Clones and Their Deduced Proteins Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT- 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (TRW Inc. Los Angeles CA) was used to determine regions of homology. The three parameters that determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith- Waterman alignments were used to display the results of the homology search. Peptide and protein sequence homologies were ascertained using the INHERIT ™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches. BLAST, which stands for Basic Local Alignment Search Tool (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF et al (1990) J Mol Biol 215:403-10), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP). An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output. IV Northern Analysis Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al. supra). Analogous computer techniques using BLAST (Altschul SF 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte, Palo Alto CA). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous. The basis of the search is the product score which is defined as: % sequence identity x % maximum BLAST score 100 and it takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1- 2% error; and at 70. the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40. although lower scores may identify related molecules. The results of the search are reported as a list of libraries in which the HPLP encoding sequence occurs. Abundance and percentage abundance of the HPLP encoding sequence are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library. V Extension of the Sequence Encoding HPLP The nucleic acid sequence of SEQ ID NO:2 is used to design oligo-nucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' sequence from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers allow the extension of the know sequence "outward" generating amplicons containing new. unknown nucleotide sequence for the region of interest (US Patent Application 08/487,112. filed June 7, 1995, specifically incorporated by reference). The initial primers are designed from the cDNA using OLIGO ® 4.06 Primer Analysis Software (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided. The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region. By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; MJ Research. Watertown MA) and the following parameters: Step 1 94° C for 1 min (initial denaturation) Step 2 65° C for 1 min Step 3 68° C for 6 min Step 4 94° C for 15 sec Step 5 65 ° C for 1 min Step 6 68° C for 7 min Step 7 Repeat step 4-6 for 15 additional cycles Step 8 94° C for 15 sec Step 9 65° C for 1 min Step 10 68° C for 7:15 min Step 1 1 Repeat step 8-10 for 12 cycles Step 12 72° C for 8 min Step 13 4° C (and holding) A 5-10 μl aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%)) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were selected and cut out of the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc). After recovery of the DNA, Klenow enzyme was used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning. After ethanol precipitation, the products are redissolved in 13 μl of ligation buffer, lμl T4-DNA ligase (15 units) and lμl T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. cells (in 40 μl of appropriate media) are transformed with 3 μl of ligation mixture and cultured in 80 μl of SOC medium (Sambrook J et al. supra). After incubation for one hour at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook J et al, supra) containing 2xCarb. The following day, several colonies are randomly picked from each plate and cultured in 150 μl of liquid LB/2xCarb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μl of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1 :10 with water, 5 μl of each sample is transferred into a PCR array. For PCR amplification, 18 μl of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions: Step 1 94° C for 60 sec Step 2 94° C for 20 sec Step 3 55° C for 30 sec Step 4 72° C for 90 sec Step 5 Repeat steps 2-4 for an additional 29 cycles Step 6 72° C for 180 sec Step 7 4° C (and holding) Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid and sequenced. VI Labeling and Use of Hybridization Probes Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs or mRNAs. Although the labeling of oligonucleotides. consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 mCi of [γ- 32 P] adenosine triphosphate (Amersham. Chicago IL) and T4 polynucleotide kinase (DuPont NEN ® , Boston MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 super fine resin column (Pharmacia). A portion containing 10 7 counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II. Eco RI, Pst I, Xba 1, or Pvu II; DuPont NEN ® ). The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40 °C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale CA) for several hours, hybridization patterns are compared visually. VII Antisense Molecules The sequence encoding HPLP, or any part thereof, is used to inhibit in vivo or in vitro expression of naturally occurring sequence. Although use of antisense oligonucleotides. comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide complementary to a portion of the coding sequence of HPLP as shown in SEQ ID NO:2 is used to inhibit expression of naturally occurring sequence. The complementary oligonucleotide is designed from the most unique 5' sequence and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of a transcript encoding HPLP by preventing the ribosome from binding. Using an appropriate portion of the leader and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or early coding sequence of the polypeptide as shown in Figure 1. VIII Expression of HPLP Expression of HPLP is accomplished by subcloning the cDNAs into appropriate vectors and transfecting the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express HPLP in E. coli. Upstream of the cloning site, this vector contains a promoter for β-galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β-galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites. Induction of an isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first seven residues of β-galactosidase. about 5 to 15 residues of linker, and the full length HPLP. The signal sequence directs the secretion of HPLP into the bacterial growth media which can be used directly in the following assay for activity. IX Assay for HPLP Activity The channel-forming ability of HPLP is assayed by monitoring efflux of Cl " or K 1 ions from vesicles containing HPLP subjected to a transmembrane ion potential. HPLP and mitochondrial cytochrome C oxidase, a proton pump, are reconstituted into lipid vesicles by sonication. 36 C1 " or 2 K + is then incorporated into the vesicles by passive diffusion, incubating the vesicles in a solution containing [ j6 Cl]-potassium chloride or [ 2 K] -potassium chloride for several hours. The vesicles are then dispersed in an appropriate reaction buffer. Addition of ascorbate and cytochrome C initiates proton uptake into the vesicles generating an interior-positive membrane potential. The voltage generated across the membrane activates gating of the HPLP ion channel. At predetermined times, aliquots of the vesicle-containing solution are removed from the reaction buffer and filtered through 0.2m membrane filters (Millipore, Marlboro MA). The vesicles are retained on the filters. The filters are rinsed and dried. Radioactivity on the filters is measured in a scintillation counter. The decrease in radioactivity on the filters as a function of reaction time gives a measure of the rate of Cl " or K" efflux through the voltage- activated HPLP ion channel. X Production of HPLP Specific Antibodies HPLP is substantially purified using PAGE electrophoresis (Sambrook, supra) is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence translated from HPLP is analyzed using DNAStar software (DNAStar Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Analysis to select appropriate epitopes, such as those near the C-terminus or in hydrophilic regions (shown in Figure 3) is described by Ausubel FM et al (supra). Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431 A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA. reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG. XI Purification of Naturally Occurring HPLP Using Specific Antibodies Naturally occurring or recombinant HPLP is substantially purified by immunoaffinity chromatography using antibodies specific for HPLP. An immunoaffinity column is constructed by covalently coupling HPLP antibody to an activated chromatographic resin such as CnBr-activated Sepharose (Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions. Membrane fractions from cells expressing HPLP are prepared by methods well known in the art. Alternatively, a recombinant HPLP fragment containing an appropriate signal sequence may be secreted in useful quantity into the medium in which transfected cells are grown. The HPLP-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HPLP (eg, high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HPLP binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and HPLP is collected. All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: INCYTE PHARMACEUTICALS, INC. (11) TITLE OF THE INVENTION: NOVEL HUMAN PHOSPHOLEMMAN-LIKE PROTEIN (ill) NUMBER OF SEQUENCES: 6 (IV) CORRESPONDENCE ADDRESS: (A ADDRESSEE: Incyte Pharmaceuticals, Inc. (B STREET: 3174 Porter Drive (C CITY: Palo Alto (D STATE: CA (E COUNTRY: U.S. ZIP: 94304 (v) COMPUTER READABLE FORM: 'A MEDIUM TYPE: Diskette (3 COMPUTER: IBM Compatible OPERATING SYSTEM: DOS (D SOFTWARE: FastSEQ Version 1.5 (vi) CURRENT APPLICATION DATA: (A APPLICATION NUMBER: To Be Assigned FILING DATE: Filed Herewith ( ll PRIOR APPLICATION DATA: (Z APPLICATION NUMBER: US 08/725,531 (B FILING DATE: 03-OCT-1996 (vm) ATTORNEY/AGENT INFORMATION: (A NAME: Billings, Lucy J. (3 REGISTRATION NUMBER: 36,749 (C REFERENCE/DOCKET NUMBER: PF-0128 PCT ;ιx) TELECOMMUNICATION INFORMATION: (A TELEPHONE: 650-855-0555 (3 TELEFAX: 650-845-4166 (2) INFORMATION FOR SEQ ID NO : 1 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vil) IMMEDIATE SOURCE: (A) LIBRARY: (B) CLONE: Consensus (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : Met Glu Leu Val Leu Val Phe Leu Cys Ser Leu Leu Ala Pro Met Val 1 5 10 15 Leu Ala Ser Ala Ala Glu Lys Glu Lys Glu Met Asp Pro Phe His Tyr 20 25 30 Asp Tyr Gin Thr Leu Arg lie Gly Gly Leu Val Phe Ala Val Val Leu 35 40 45 Phe Ser Val Gly He Leu Leu He Leu Ser Arg Arg Cys Lys Cys Ser 50 " 55 60 Phe Asn Gin Lys Pro Arg Ala Pro Gly Asp Glu Glu Ala Gin Val Glu 65 70 75 80 Asn Leu He Thr Ala Asn Ala Thr Glu Pro Gin Lys Ala Glu Asn 85 90 95 (2) INFORMATION FOR SEQ ID NO : 2 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 591 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ill MOLECULE TYPE: cDNA (vn) IMMEDIATE SOURCE: (A) LIBRARY: (B) CLONE: Consensus (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : CTCCTGGCAG GGCC-GAGGT GGATGGGGCT TGAAAAGGGG GTTCAAGGCA GCAGATCTAT 60 GGTTGCAGAC GCCATGGAGT TGGTGCTGGT CTTCCTCTGC AGCCTGCTGG CCCCCATGGT 120 CCTGGCCAGT GCAGCTGAAA AGGAGAAGGA AATGGACCCT TTTCATTATG ATTACCAGAC 180 CCTGAGGATT GGGGGACTGG TGTTCGCTGT GGTCCTCTTC TCGGTTGGGA TCCTCCTTAT 240 CCTAAGTCGC AGGTGCAAGT GCAGTTTCAA TCAGAAGCCC CGGGCCCCAG GAGATGAGGA 300 AGCCCAGGTG GAGAACCTCA TCACCGCCAA TGCAACAGAG CCCCAGAAAG CAGAGAACTG 360 AAGTGCAGCC ATCAGGTGGA AGCCTCTGGA ACCTGAGGCG GCTGCTTGAA CCTTTGGATG 420 CAAATKTCGA TGCTTAAGAA AACCGGCCAC TTCAGCAACA GCCCTTTCCC CAGGAGAAGC 480 CAAGAACTTG TGTGTCCCCC ACCCTATCCC CTCTAACACC ATTCCTCCAC CTGATGATGC 540 AACTAACACT TGCCTCCCCA CTGCAGCCTG CGGTCCTGCC CACCTCCCGA T 591 (2) INFORMATION FOR SEQ ID NO: 3: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 92 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n) MOLECULE TYPE: peptide (vn) IMMEDIATE SOURCE: (A) LIBRARY: GenBank (B) CLONE: 108084 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : Met Ala Pro e- His His He Leu Val Leu Cys Val Gly Phe Leu Thr 1 5 10 15 Thr Ala Thr Ala Glu Ala Pro Gin Glu His Asp Pro Phe Thr Tyr Asp 20 25 30 Tyr Gin Ser e- Arg He Gly Gly Leu He He Ala Gly He Leu Phe 35 40 45 He Leu Gly He Leu He Val Leu Ser Arg Arg Cys Arg Cys Lys Phe 50 55 60 Asn Gin Gin Gin Arg Thr Gly Glu Pro Asp Glu Glu Glu Gly Thr Pne 65 70 75 80 Arg Ser Ser He Arg Arg Leu Ser Thr Arg Arg Arg 85 90 (2) INFORMATION FOR SEQ ID NO: 4: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vn) IMMEDIATE SOURCE: (A) LIBRARY: GenBank (B) CLONE: 1085026 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Gin Lvs Val Thr Leu Gly Leu Leu Val Phe Leu Ala Gly Phe Pro 1 * 5 10 15 Val Leu Asp Ala Asn Asp Leu Glu Asp Lys Asn Ser Pro Phe Tyr Tyr 20 " 25 30 ASD Trp his Ser Leu Gin Val Gly Gly Leu He Cys Ala Gly Val Leu 35 40 45 Cys Ala Met Gly He He He Val Met Ser Ala Lys Cys Lys Cys Lys 50 55 60 Phe Gly Gin Lys Ser Gly His His Pro Gly Glu Thr Pro Pro Leu He 65 70 75 80 Thr Pro Gly Ser Ala Gin Ser 85 (2) INFORMATION FOR SEQ ID NO : 5 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptiαe (vii) IMMEDIATE SOURCE: (A) LIBRARY: GenBank (B) CLONE: 951423 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : Met Glu Gly He Thr Cys Ala Phe Leu Leu Val Leu Ala Gly Leu Pro 1 5 10 15 Val Leu Glu Ala Asn Gly Pro Val Asp Lys Gly Ser Pro Phe Tyr Tyr 20 25 30 Asp Trp Glu Ser Leu Gin Leu Gly Gly Met He Phe Gly Gly Leu Leu 35 40 45 Cys He Ala Gly He Ala Met Ala Leu Ser Gly Lys Cys Lys Cys Arg 50 55 60 Arg Asn His Thr Pro Ser Ser Leu Pro Glu Lys Val Thr Pro Leu He 65 70 75 80 Thr Pro Gly Ser Ala Ser Thr 85 (2) INFORMATION FOR SEQ ID NO : 6 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vn) IMMEDIATE SOURCE: (A) LIBRARY: GenBank (B) CLONE: 51112 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : Met Val Ala Val Gin Gly Thr Glu Asn Pro Phe Glu Tyr ASD Tyr Glu 1 5 10 15 Thr Val Arg Lys Gly Gly Leu He Phe Ala Gly Leu Ala Phe Val Val 20 25 30 Gly Leu Leu He He Leu Ser Lys Arg Phe Arg Cys Gly Gly Gly Lys 35 40 45 Lys His Arg Gin Val Asn Glu Asp Glu Leu 50 55

Claims: CLAIMS 1. A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO: l. or fragments thereof. 2. An isolated and purified polynucleotide sequence encoding the polypeptide of claim 1. 3. An isolated polynucleotide sequence comprising the nucleic acid sequence of SEQ ID NO: 2 or variants thereof. 4. An isolated polynucleotide sequence which is complementary to SEQ ID NO:2 or variants thereof. 5. An isolated polynucleotide sequence which hybridizes under stringent conditions to SEQ ID NO:2. 6. A hybridization probe comprising SEQ ID NO:2. or fragments thereof. 7. A recombinant expression vector containing the polynucleotide sequence of claim 3. 8. A recombinant host cell containing the expression vector of claim 7. 9. A method for producing the polypeptide of SEQ ID NO: 1 , or fragments thereof, the method comprising the steps of: a) culturing the host cell of claim 8 under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture. 10. A pharmaceutical composition comprising the polypeptide of SEQ ID NO:l in conjunction with a pharmaceutically acceptable excipient. 1 1. A purified antibody which binds specifically to the polypeptide of claim 1. 12. A purified antagonist which specifically binds to and modulates the activity of the polypeptide of claim 1. 13. A pharmaceutical composition comprising an antagonist of the polypeptide of claim 1 in conjunction with a pharmaceutically acceptable excipient. 14. A purified agonist which specifically binds and modulates the activity of the polypeptide of claim 1. 15. A pharmaceutical composition comprising an agonist of the polypeptide of claim 1 in conjunction with a pharmaceutically acceptable excipient. 16. A method for the detection of polynucleotides encoding SEQ ID NO: l in a biological sample comprising the steps of: a) hybridizing the probe of claim 6 to nucleic acid material, thereby forming a hybridization complex, and b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human phospholemman-like protein in said biological sample. 17. The method of claim 16 wherein before hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.

Inventors: BANDMAN OLGA, GOLI SURYA K, BANDMAN, OLGA, GOLI, SURYA, K.
Applicants: BANDMAN OLGA, GOLI SURYA K, INCYTE PHARMA INC, BANDMAN, OLGA, GOLI, SURYA, K., INCYTE PHARMACEUTICALS, INC.
Application year: 1997
Main classification: C12N15
IPC codes: A61K31, A61K35, A61K38, A61K39, A61K45, A61K48, A61P25, A61P43, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33